


**Figure 1**



**Figure 2**







Figure 3



**Figure 4**






**Figure 5**



**Figure 6**  
**Compound A Reduces Lung Permeability as Measured**  
**by Fluorescence Following RITC-Dextran**  
**Administration to Rats with Bleomycin-Induced Lung**

	<b>Saline/Vehicle</b>	<b>Injury Bleomycin/Vehicle</b>	<b>Bleomycin/40208</b>
--	-----------------------	-------------------------------------	------------------------






# Figure 7

## Compound A Treatment Reduces Tissue Damage in Bleomycin 5 Day Rat Lung Injury Model


saline

Bleomycin + vehicle


Bleomycin + 40208




**Figure 8**



**Figure 9**




**Figure 10**



**Figure 11**  
**Compound A Treatment Reduces Fibrosis in 14 Day**  
**Bleomycin Rat Lung Injury Model**

**Vehicle**

**Compound A**



Hematoxylin and eosin staining, 100x magnification

Figure 12

Compound A Treatment Reduces  
Fibrosis in 14 Day Bleomycin Rat Lung  
Injury Model

Vehicle

Compound A

